ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
宜明昂科生物醫藥技術（上海）股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 1541)

ANNOUNCEMENT OF ANNUAL RESULTS FOR THE YEAR ENDED DECEMBER 31, 2024 AND PROPOSED CHANGE IN USE OF PROCEEDS

The board (the "**Board**") of directors (the "**Directors**") of ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (the "**Company**") is pleased to announce the audited consolidated results of the Company and its subsidiaries (collectively, the "**Group**") for the year ended December 31, 2024, together with comparative figures for the same period of 2023. These annual results have been reviewed by the Audit Committee and agreed by the Company's auditor, Messrs. Deloitte Touche Tohmatsu.

In this announcement, "**we**", "**us**" and "**our**" refer to the Company or where the context otherwise requires, the Group. Certain amounts and percentage figures included in this announcement have been subject to rounding adjustments or have been rounded to one or two decimal places, as appropriate. Any discrepancies in any table, chart or elsewhere totals and sums of amounts listed therein are due to rounding. Unless otherwise defined herein, capitalized terms used in this announcement shall have the same meanings ascribed thereto in the Prospectus of the Company dated August 24, 2023.

BUSINESS HIGHLIGHTS

During the Reporting Period, we continued rapidly advancing the development of our drug pipeline, including the following milestones and achievements.

Progress of Our Oncology Products

Progress of Core Product

- *IMM01 (timdarpacept) (SIRPα-Fc Fusion Protein)*

  - We have completed the enrollment of patients for the Phase II clinical trial of IMM01 in combination with azacitidine for the first-line treatment of higher-risk myelodysplastic syndrome (MDS) in June 2023. As of December 31, 2024, the median duration of follow-up was 26.0 months (95%CI, 23.5–28.3). Among the 51 efficacy-evaluable patients, overall response rate (ORR) was 64.7%, including 33.3% complete response (CR) rate, 15.7% marrow CR (mCR) with hematologic improvement (HI), 3.9% HI and 11.8% mCR alone. The Phase II study results were selected for oral presentation at the American Society of Clinical Oncology (ASCO) in 2024. Mature survival endpoints, including median progression-free survival (PFS), will be disclosed at a forthcoming international oncology conference in 2025.

  - We have completed the enrollment of patients for the Phase II clinical trial of IMM01 in combination with azacitidine for the first-line treatment of chronic myelomonocytic leukemia (CMML) in May 2023. As of December 31, 2024, the median duration of follow-up was 21.0 months (95%CI, 19.3–23.3). Among 22 efficacy evaluable patients, overall response rate (ORR) was 72.7%, including 27.3% CR, 13.6% mCR with 4.5% HI and 27.3% mCR alone. The Phase II study results were selected for oral presentation at the European Society for Medical Oncology (ESMO) in 2024. Mature survival endpoints, including median PFS, will be disclosed at a forthcoming international oncology conference in 2025.

- We have completed the enrollment of patients for the Phase II clinical trial of IMM01 in combination with tislelizumab, targeting relapsed or refractory (R/R) classical Hodgkin lymphoma (cHL) patients who relapsed or progressed after the treatment of PD-1 inhibitors in December 2023. As of December 31, 2024, among 33 evaluable patients, 8 achieved CR, 15 achieved partial response (PR), resulting in an ORR of 69.7% and CRR of 24.2%. These results demonstrate encouraging antitumor efficacy, along with favorable tolerability and safety profiles. The Phase II study results were selected for oral presentation at ASCO and ESMO respectively and were selected for the Best of ASCO® program at the 2024 China Clinical Oncology Annual Progress Symposium (BOC) & Best of ASCO® 2024 China (BOC/BOA).

- We have obtained approval from the National Medical Products Administration of the People's Republic of China (NMPA) for the protocol of the Phase III clinical trial of IMM01 in combination with tislelizumab in prior PD-(L) 1-refractory cHL in April 2024. The first patient was dosed in July 2024.

- We have obtained an Investigational New Drug (IND) approval from NMPA for Phase III clinical trial of IMM01 in combination with azacitidine for the first-line treatment of higher-risk myelodysplastic syndrome (HR-MDS) in May 2024.

- We have obtained an IND approval from NMPA for a Phase III clinical trial of IMM01 in combination with azacitidine for the first-line treatment of CMML in June 2024. The first patient was dosed in November 2024.

- We have obtained an IND approval from NMPA for a clinical trial of IMM01 in combination with IMM2510 and with or without chemotherapy, for the treatment of advanced malignant tumors in March 2025.

Progress of Other Selected Products

Clinical Stage Products

- *IMM2510 (palverafusp alfa) (VEGF×PD-L1)*

  - We have completed the enrollment of patients for the Phase I dose-escalation study of IMM2510 in September 2023. A total of 33 patients with advanced/metastatic solid tumors were enrolled and dosed. The recommended Phase II dose (RP2D) has been determined. The clinical data from the Phase I trial of IMM2510 has demonstrated tolerable safety and promising antitumor activity particularly for treatments of advanced solid tumors. We have observed three patients who confirmed PR and seven patients with SD and four of them had over 15% tumor shrinkage.

  - We dosed the first patient in the Phase Ib/II clinical trial of IMM2510 monotherapy in China in November 2023. As of December 31, 2024, 74 patients were enrolled and dosed, with preliminary data demonstrating promising efficacy and favorable safety profile. As of December 31, 2024, we have enrolled a total of 107 patients, including the 33 patients from the Phase I dose-escalation study.

  - We received IND approval from the NMPA for a clinical trial of IMM2510 in combination with IMM27M for advanced solid tumors in October 2023. The IMM2510–002 study, a Phase Ib/II investigation of IMM2510 combined with IMM27M for the treatment of R/R solid tumors, was initiated in July 2024. The first patient was dosed in July 2024.

  - IMM2510–003, a Phase Ib/II study of IMM2510 in combination with chemotherapy for first line NSCLC was initiated and the first patient was dosed in December 2024. We anticipate releasing initial clinical data as early as the second half of 2025.

- *IMM27M (tazlestobart) (CTLA-4 ADCC-enhanced mAb)*

  - We have completed the enrollment of patients for the Phase I dose-escalation study of IMM27M, and the preliminary data has demonstrated that IMM27M is safe and well tolerated. Two confirmed PRs were achieved in heavily treated advanced solid tumors patients as of December 31, 2024.

  - A RP2D dose has been determined for Phase I cohort expansion. Various advanced solid tumor patients have been enrolled. We have dosed the first patient in a cohort expansion study for hormone receptor positive (HR+) and HER2 negative metastatic breast cancer in September 2024. Preliminary data from both the dose-escalation and early cohort expansion Phase indicate that IMM27M is safe and well tolerated.

- *IMM0306 (amulirafusp alfa)(CD47×CD20)*

  - We have completed the enrollment of patients for phase Ib dose escalation clinical trial of IMM0306 in combination of lenalidomide for the R/R follicular lymphoma (FL) and marginal zone lymphoma (MZL). As of December 31, 2024, a total of 11 patients were enrolled at two dose levels (1.6 mg/kg and 2.0 mg/kg). Among 11 efficacy-evaluable patients in the phase Ib study, 3 CRs (all FL) and 7 PRs (5 FL, 2 MZL) were observed. The ORR and CRR were 90.9% and 27.3%, respectively. IMM0306 at the dose of 1.6 mg/kg in combination with lenalidomide at 20 mg/day (RP2D) was well-tolerated and demonstrated a robust preliminary antitumor activity in patients with R/R FL and MZL.

  - We have dosed the first patient for Phase IIa dose expansion clinical trial in March 2024. As of December 31, 2024, a total of 36 R/R FL patients who relapsed from or were refractory to at least 1 line of therapy were enrolled. Promising antitumor activity was observed alongside a manageable safety profile. The detailed data will be disclosed at an upcoming international oncology conference in 2025.

- *IMM2520 (CD47×PD-L1)*

  - As of December 31, 2024, 26 patients have been enrolled and dosed. The preliminary data has demonstrated that IMM2520 is safe and well tolerated. One PR and two SDs with tumor shrinkage over 10% were achieved.

Progress of Our Non-oncology Products

Autoimmune Diseases Products

- *IMM0306 (amulirafusp alfa) (CD47×CD20)*
    - We have dosed the first patient in Phase Ib trial for systemic lupus erythematosus (SLE) in October 2024, completed enrollment of the first dose cohort (7 patients) and initiated the second dose cohort enrollment for SLE in February 2025.
    - We have dosed the first patient in Phase Ib trial for neuromyelitis optica spectrum disorders (NMOSDs) in December 2024, completed enrollment of the first dose cohort (3 patients) and initiated the second dose cohort enrollment for NMOSD in February 2025.
    - We have obtained IND approvals for the Phase II trial for lupus nephritis (LN) in December 2024.
    - We are preparing to submit the IND applications to the U.S. Food and Drug Administration (FDA) and expect receiving IND approvals for SLE in the second half of 2025.

Metabolic Diseases and Cardiovascular Diseases Products

- *IMM01 (timdarpacept) (SIRPα-Fc Fusion Protein)*
    - IND-enabling study is currently ongoing for IMM01 for the treatment of atherosclerosis.
- *IMM72/IMC-003 (ActRIIA fusion protein)*
    - We have submitted pre-IND documents to CDE and expect to obtain IND approval in June 2025.
- *IMM7220/IMC-010 (GLP-1 x ActRIIA Bispecific Molecule)*
    - The in vitro study demonstrated its potential for treating obesity and promoting muscle growth.
    - We are proceeding with in vivo efficacy study.

Business Development

On August 1, 2024, the Company reached a license and collaboration agreement (the "**Agreement**") with Axion Bio, Inc. (a wholly-owned subsidiary of Instil Bio Inc. (TIL US)) (formerly known as SynBioTx Inc.), pursuant to which Instil will in-license the commercial rights outside the Greater China region, including mainland China, Hong Kong Special Administrative Region of China, Macau Special Administrative Region of China and Taiwan (the "**Greater China region**") to our proprietary PD-L1xVEGF bispecific molecule IMM2510 (palverafusp alfa), as well as our next-generation anti-CTLA-4 antibody (ADCC+) IMM27M (tazlestobart). Pursuant to the Agreement, the Company is entitle to an upfront payment and potential near-term payments of up to US$50 million as well as potential additional development, regulatory, and commercial milestones payments of up to US$2.1 billion, plus single digit to low double-digit percentage royalties on global (outside the Greater China region) net sales.

As of December 31, 2024, we have received the upfront payment and near-term payments of US$15 million.

FINANCIAL HIGHLIGHTS

- **Revenue** was RMB74.1 million for the year ended December 31, 2024, representing an increase of RMB73.7 million from RMB0.4 million for the year ended December 31, 2023, primarily attributable to the upfront payment and near-term payments we have received pursuant to the license and collaboration agreement the Company have reached with Axion Bio, Inc.

- **Research and development expenses** increased by 10.6% from RMB291.9 million for the year ended December 31, 2023 to RMB322.8 million for the year ended December 31, 2024, primarily attributable to (i) an increase of RMB43.6 million in preclinical and CMC expenses, primarily due to the increased manufacturing and CDMO expenses of IMM2510 and IMM0306 for the use in their clinical trials; and (ii) an increase of RMB7.4 million in salaries and related benefit costs due to the continuous expansion of our clinical team throughout 2024, in line with our continuous research and development efforts in advancing and expanding our pipeline of drugs; partially offset by a decrease of RMB 18.3 million in clinical trial expenses and Share-based payments due to (i) the decrease of RMB 4.0 million in clinical CRO expenses and laboratories expenses; and (ii) a decrease of RMB14.3 million in share-based payments, resulting from a decrease in the number of restricted shares vested for the year ended December 31, 2024.

Overview

We are a science-driven biotechnology company dedicated to the development of innovative immuno-oncology therapies. Incorporated in 2015, we stand out as one of the few biotechnology companies globally adopting a systematic approach to harness both the innate and adaptive immune systems. Strictly adhering to the "Drug-by-Design" concept and leveraging our R&D platform, we have designed a robust pipeline of over ten innovative drug candidates with 11 ongoing clinical programs. Anchored by a deep and broad innate-immunity-based asset portfolio, our pipeline reflects our extensive understanding into the frontiers of cancer biology and immunology, and our expertise in turning scientific research into drug candidates.

Product Pipeline

The following diagram summarizes the development status of our selected drug candidates as of the date of this announcement:

Notes:

(1) All of the Company's clinical- and IND-stage drug candidates are classified as Category 1 innovative drugs, and preclinical- and discovery-stage drug candidates are expected to be classified as Category 1 innovative drugs, in accordance with relevant laws and regulation in China.

(2) The trial is mainly designed to target the first-line treatment of higher-risk MDS (patients who fall into higher-risk group categories in the original or revised International Prognostic Scoring System).

(3) This combination of IMM01 and tislelizumab targets prior PD-(L) 1-refractory cHL.

Abbreviations: MDS refers to myelodysplastic syndrome; CMML refers to chronic myelomonocytic leukemia; cHL refers to classical Hodgkin lymphoma; FL refers to follicular lymphoma; MZL refers to marginal zone lymphoma; IND refers to investigational new drug; CMC refers to chemistry, manufacturing, and controls; ADCC refers to antibody-dependent cellular cytotoxicity; TNBC refers to triple-negative breast cancer; NSCLC refers to non-small cell lung cancer; SLE refers to systemic lupus erythematosus; LN refers to lupus nephritis; NMOSD refers to neuromyelitis optica spectrum disorder; PAH refers to pulmonary arterial hypertension.

Business Review

Our Product Candidates

During the Reporting Period, we made significant progress advancing our pipeline candidates and business operations. Our key achievements and planned next steps as of the date of this announcement along include:

- *IMM01 (timdarpacept) (SIRPα-Fc Fusion Protein)*

  - IMM01, our Core Product, is an innovative CD47-targeted molecule. It is the first SIRPα-Fc fusion protein to enter into clinical stage in China. IMM01 designed with IgG1 Fc can fully activate macrophages via a dual mechanism — simultaneously blocking the "don't eat me" signal by disrupting CD47/SIRPα interaction and delivering the "eat me" signal through the engagement of activating Fcγ receptors on macrophages. Furthermore, the CD47-binding domain of IMM01 was specifically engineered to avoid human red blood cell (RBC) binding. With the differentiated molecule design, IMM01 has achieved a favorable safety profile and demonstrated its ability to activate macrophages. Moving forward, we may actively explore IMM01's therapeutic potential in other indications and seek collaboration opportunities.

- During the Reporting Period and up to the date of this announcement, we have achieved the following progress and milestones:

  - Combination Therapy with Azacitidine

    - We have completed the enrollment of patients for the Phase II clinical trial of IMM01 in combination with azacitidine for the first-line treatment of higher-risk MDS in June 2023. 57 patients were enrolled in the study. As of December 31, 2024, the median duration of follow-up was 26.0 months (95%CI, 23.5–28.3). Among the 51 efficacy evaluable patients, overall response rate (ORR) was 64.7%, including 33.3% complete response (CR) rate, 15.7% marrow CR (mCR) with hematologic improvement (HI), 3.9% HI and 11.8% mCR alone. Among patients treated for ≥ 6 months, the ORR reached 89.7% (26/29), and the CRR was 58.6% (17/29), demonstrating increasing efficacy with prolonged treatment duration. Mature survival endpoints, including median progression-free survival (PFS), will be disclosed at a forthcoming international oncology conference in 2025. The most common ≥G3 treatment related adverse events (TRAEs) (≥10%) included leukopenia (78.9%), thrombocytopenia (66.7%), neutropenia (66.7%), lymphopenia (57.9%), anemia (45.6%), infection (17.5%) and pneumonia (12.3%). Without having to resort to priming dose, only 1 patient (1.8%) had Grade 3 hemolysis occurred, but resolved after treatment. IMM01 (without low-dose priming) combined with azacitidine were well tolerated and showed exciting efficacy results in patients with treatment-naive higher-risk MDS, as demonstrated in the diagram below:

Duration of Treatment and Best Response (1L HR-MDS)

Best Percent Change from Baseline in the Blast Cells in the Bone Marrow (1L HR-MDS)



- A randomized, controlled, double-blind, multicenter, Phase III study (IMM01-009) of IMM01 in combination with azacitidine in patients with newly diagnosed higher-risk MDS was approved by NMPA in May 2024.

- We completed the enrollment of patients for the Phase II clinical trial of IMM01 in combination with azacitidine for the first-line treatment of CMML in May 2023. A total of 24 patients were enrolled. As of December 31, 2024, the median duration of follow-up was 21.0 months (95%CI, 19.3–23.3). Among 22 efficacy evaluable patients, ORR was 72.7%, including 27.3% CR, 13.6% mCR with 4.5% HI and 27.3% mCR alone. Among patients treated for ≥ 6 months, the ORR reached 84.6% (11/13), and the CRR was 46.2% (6/13), revealing increasing efficacy with prolonged treatment duration. Mature survival endpoints, including median progression-free survival (PFS), will be disclosed at a forthcoming international oncology conference in 2025. The most common ≥Grade 3 TRAEs (≥10%) included lymphopenia (66.7%), leukopenia (62.5%), neutropenia (58.3%), thrombocytopenia (50.0%), anemia (29.2%) and pneumonia (16.7%). IMM01, without

the use of low-dose priming, combined with azacitidine, was well tolerated in 1L CMML. The combination of IMM01 with azacitidine, showed exciting efficacy results for patients with treatment-naive CMML, as demonstrated in the diagram below:

Duration of Treatment and Best Response (1L CMML)



Best Percent Change from Baseline in the Blast Cells in the Bone Marrow (1L CMML)



- The FDA has granted an orphan-drug designation to IMM01 in combination with azacitidine for the treatment of CMML in November 2023.

- A randomized, controlled, double-blind, multicenter, Phase III study (IMM01-010) of IMM01 in combination with azacitidine in patients with newly diagnosed CMML was approved by the NMPA in June 2024. The first patient was dosed in November 2024.

o Combination Therapy with Tislelizumab

- We have dosed the first patient for the Phase II clinical trial of IMM01 in combination with tislelizumab on January 19, 2023, targeting R/R cHL patients who had relapsed or progressed after the treatment with PD-1 inhibitors, and completed the Phase II enrollment in December 2023. As of December 31, 2024, 33 cHL R/R patients were enrolled. Among 33 efficacy evaluable patients, 8 achieved CR and 15 achieved PR, resulting in an ORR of 69.7% and a CRR of 24.2%. No reported cases of hemolytic anemia or hemolysis in any of the patients. No patients experienced TRAEs leading to study drug discontinuation or death. These results demonstrate encouraging antitumor efficacy, along with favorable tolerability and safety profiles.

- The following diagrams illustrate the interim efficacy data of the combination of IMM01 and tislelizumab as of December 31, 2024:

Best Percentage Change from Baseline in Target Lesion



Duration of Treatment and Response



Change in Target Lesion Tumor Size



- We received approval from the NMPA for the protocol of the Phase III clinical trial of IMM01 in combination with tislelizumab versus physician's choice of chemotherapy in prior PD-(L) 1-refractory cHL in April 2024. The first patient was dosed in July 2024.

- Combination Therapy with IMM2510

  - We have obtained an IND approval from NMPA for a clinical trial of IMM01 in combination with IMM2510 and with or without chemotherapy, for the treatment of advanced malignant tumors in March 2025.

- Potential Therapy for Treating Atherosclerosis

  - Based on a solid scientific basis, IMM01 may also be effective in treating atherosclerosis by blocking the CD47/SIRPα signaling pathway and inducing macrophages to phagocytose the atherosclerotic plaque. IND-enabling study is currently ongoing for IMM01 for the treatment of atherosclerosis.

Warning under Rule 18A.08(3) of the Listing Rules: There is no assurance that IMM01 will ultimately be successfully developed and marketed by our Company.

- *IMM2510 (palverafusp alfa)(VEGF×PD-L1)*

  - IMM2510 is a bispecific molecule with the mAb-Trap structure that targets VEGF and PD-L1 for the treatment of solid tumors. By targeting VEGF and PD-L1, IMM2510 is able to activate T-cell tumor killing activities and simultaneously inhibit tumor angiogenesis and tumor growth. Moreover, IMM2510 can also activate NK cells and macrophages through Fc-mediated ADCC/ADCP activities.

    - Monotherapy

      - We completed the enrollment of patients for the Phase I dose-escalation study of IMM2510 in September 2023. 33 patients with advanced/metastatic solid tumors were enrolled and dosed. There was no DLT observed. The RP2D has been determined. The clinical data as of December 31, 2024 from the Phase I trial of IMM2510 has demonstrated tolerable safety and promising antitumor activity. As of December 31, 2024, we have observed three patients who confirmed PR. We observed seven patients with SD and four of them had over 15% tumor shrinkage. The following diagrams illustrate the interim efficacy data of IMM2510 monotherapy:

Duration of Treatment and Best Response



Best Percent Change from Baseline in Target Lesions



Change in Target Lesion Tumor Size



- As of December 31, 2024, 74 patients were enrolled and dosed in Phase Ib/ II clinical trial. All patients enrolled had previously failed standard of care therapy, over 60% of which had prior immunotherapy or VEGF-targeted therapy history. Promising preliminary efficacy was found in non-small cell lung cancer, triple-negative breast cancer, soft tissue sarcoma, hepatocellular cancer, colorectal cancer and renal cell cancer.

- As of December 24, 2024, a favorable safety profile was observed in a phase Ib/II trial of the 20 mg/kg dose administered every two weeks (Q2W), with the majority TRAEs being grade 1 or 2.

o Combination therapy with chemotherapy

- We have received IND approval from the NMPA for a Phase II clinical trial of IMM2510 in combination with chemotherapy for 1L NSCLC and TNBC in November 2023. We have dosed first patient for NSCLC cohort in December 2024. We anticipate releasing initial clinical data as early as the second half of 2025.

o Combination Therapy with IMM27M

- We received IND approval from the NMPA for a clinical trial of IMM2510 in combination with IMM27M for advanced solid tumors in October 2023. The IMM2510–002 study (IMM2510+IMM27M Phase Ib/II study for R/R solid tumor) was initiated in July 2024. The first patient was dosed on July 23, 2024.

- *IMM27M (tazlestobart) (CTLA-4 ADCC-enhanced mAb)*

  - IMM27M is a new generation CTLA-4 antibody with enhanced ADCC activity through genetic engineering modification. As a protein receptor that can be found on the activated T cells, CTLA-4 can downregulate immune responses by binding to CD80/CD86, its natural ligands found on the surface of antigen presenting cells, delivering inhibitory signal and thus suppressing T-cell immune function. CTLA-4 antibodies can block the interaction between CTLA-4 and CD80/CD86, and thus enhance immune responses of T cells to tumor antigens.

  - We have completed the enrollment of patients for the Phase I dose-escalation study of IMM27M, and the preliminary data has demonstrated that IMM27M is safe and well tolerated. There was no DLT observed. The RP2D has been determined. In the Phase I dose-escalation study, we have observed 2 confirmed PRs, by December 31, 2024.

  - We have dosed the first patient in a cohort expantion study for hormone receptor positive (HR+) and HER2 negative metastatic breast cancer in September, 2024.

- *IMM0306 (amulirafusp alfa) (CD47×CD20)*

  - IMM0306 (amulirafusp alfa) is a bispecific molecule that simultaneously targets both CD47 and CD20, and is the first CD47 and CD20 dual-targeting bispecific that has entered into clinical stage globally. Based on our mAb-Trap platform, we designed the molecule of IMM0306 to consist of the CD47-binding domain and an ADCC-enhanced IgG1 Fc fragment which is capable of inducing full macrophage activation and greatly improved antibody-dependent cellular phagocytosis (ADCP) and antibody-dependent cellular cytotoxicity (ADCC) activity, resulting in strong antitumor immune responses.

  - During the Reporting Period and up to the date of this announcement, we have achieved the following progress and milestones:

    - Combination Therapy with Lenalidomide

      - We dosed the first patient in the Phase Ib/IIa clinical trial, a combination study of IMM0306 and lenalidomide for R/R CD20-positive B-NHL in June 2023.

- We have completed the enrollment of patients for phase Ib dose escalation clinical trial of IMM0306 in combination of lenalidomide for the R/R follicular lymphoma (FL) and marginal zone lymphoma (MZL). As of December 31, 2024, a total of 11 patients were enrolled at two dose levels (1.6 mg/kg and 2.0 mg/kg). Among 11 efficacy-evaluable patients in the phase Ib study, 3 CRs (all FL) and 7 PRs (5 FL, 2 MZL) were observed. The ORR and CRR were 90.9% and 27.3%, respectively. IMM0306 at the dose of 1.6 mg/kg in combination with lenalidomide at 20 mg/day (RP2D) was well-tolerated and demonstrated a robust preliminary antitumor activity in patients with R/R FL and MZL.

- We have dosed the first patient for Phase IIa dose expansion clinical trial in March 2024. As of December 31, 2024, a total of 36 R/R FL patients who relapsed from or were refractory to at least 1 line of therapy were enrolled. Promising antitumor activity was observed alongside a manageable safety profile. The detailed data will be disclosed at an upcoming international oncology conference in 2025.

- The following diagrams illustrate the interim efficacy data of the combination of IMM0306 and lenalidomide in Phase Ib trial:

Duration of Treatment and Best Response in Phase Ib



Best Percentage Change from Baseline in Target Lesion in Phase Ib



Change in Target Lesion Tumor Size in Phase Ib



o Potential Therapy for Treating Autoimmune Diseases

- B-cell depletion observed in IMM0306 clinical studies serves as a strong basis for its treatment of autoimmune diseases.

- We have dosed the first patient in Phase Ib trial for systemic lupus erythematosus (SLE) in October 2024, completed enrollment of the first dose cohort (7 patients) and initiated the second dose cohort enrollment for SLE in February 2025.

- We have dosed the first patient in Phase Ib trial for neuromyelitis optica spectrum disorders (NMOSDs) in December 2024, completed enrollment of the first dose cohort (3 patients) and initiated the second dose cohort enrollment for NMOSD in February 2025.

- We have obtained IND approvals for the Phase II trial for lupus nephritis (LN) in December, 2024.

- We are preparing to submit the IND applications to the FDA and expect receiving IND approvals for SLE in the second half of 2025.

- *IMM2520 (CD47×PD-L1)*

  - IMM2520 is a CD47 and PD-L1 dual-targeting bispecific molecule for the treatment of solid tumors. IMM2520 consists of a PD-L1 antibody with an engineered ADCC-enhanced IgG1 Fc region, linked to the same CD47-binding domain used in IMM01 at the N-terminus of heavy chains. This unique structure allows our CD47-based bispecific molecules to avoid RBC binding, thus enabling the adoption of an ADCC-enhanced IgG1 Fc fragment to fully activate macrophages and induce enhanced ADCP and ADCC activity, resulting in potent integrated antitumor immune responses.

  - We have dosed the first patient at 0.1 mg/kg dose level on March 23, 2023 in the Phase I study of IMM2520 targeting solid tumor indications, with a particular focus on solid tumors that are generally resistant or not sensitive to currently available immunotherapies. As of December 31, 2024, 26 patients in total have been enrolled and dosed at 6 dose levels (from 0.1mpk to 4mpk). As of December 31, 2024, one PR and two SDs with over 10% tumor shrinkage have been observed. The patient had PR was diagnosed with small cell lung cancer who failed prior immunotherapy, indicating potential efficacy among solid tumor patients.

During the past year, we have also expanded our early research and development efforts into non-oncology therapeutic areas, and achieved significant progress, including:

- *IMM72/IMC-003 (ActRIIA fusion protein)*

  - IMM72/IMC-003 is a new generation ActRIIA fusion protein through genetic engineering modification with better activity and quality attributes than sotatercept. We have completed the pilot efficacy study in rat models of PAH. We have submitted pre-IND documents to the CDE and expect to obtain IND approval in June 2025.

- *IMM7220/IMC-010 (GLP-1 × ActRIIA Bispecific Molecule)*

  - IMM7220/IMC-010 is a bispecific Fc fusion protein targeting ActRIIA ligands and GLP-1R, indicated for the treatment of patients with obesity (lose fat and build muscle). We are proceeding with in vivo efficacy study.

Activity



	IMC-010	GLP-Fc
EC50	6.344	3.089



	IMC-010	IMC-003
IC50	0.1466	0.7803

- *IMM67 (recombinant human hyaluronidase)*

  - IMM67 is a recombinant human hyaluronidase engineered and expressed by mammalian cells. Our IMM67 can locally degrade hyaluronan in the subcutaneous space and temporarily remove the barrier to fluid flow, and thus overcome volume limitation to subcutaneous injection. We have completed the CMC of IMM67 as a pharmaceutical excipient. Non-clinical study is currently in progress, with registration filing to the NMPA anticipated by the first quarter of 2025.

Warning under Rule 18A.08(3) of the Listing Rules: There is no assurance that IMM2510, IMM27M, IMM0306, IMM2520, IMM72/IMC-003, IMM7220/IMC-010 and IMM67 will ultimately be successfully developed and marketed by our Company.

Business Development

On August 1, 2024, the Company and Axion Bio, Inc. (formerly known as SynBioTx Inc.), a wholly-owned subsidiary of Instil Bio, Inc. (NASDAQ: TIL) ("**Instil**"), have entered into a license and collaboration agreement, pursuant to which the Company agreed to grant Axion Bio, Inc. an exclusive license to research, develop and commercialize IMM2510 (palverafusp alfa) and IMM27M (tazlestobart), outside the Greater China region.

The Company has received an upfront payment and near-term payment in aggregate of US$15 million and anticipates to receive the remaining potential near-term payments of up to US$35 million, as well as milestone payments of up to US$2.1 billion in commercial, development and regulatory milestones (including up to US$270 million in longer term development and regulatory milestones and up to US$1.8 billion in commercial milestones) plus single-digit to low double digit percentage royalties on global net sales outside the Greater China Region.

Instil anticipates initiating a U.S. clinical trial of AXN-2510/IMM2510 in combination with chemotherapy for 1L NSCLC patients before the end of 2025, assuming the necessary regulatory approvals are obtained. Therefore, the Company may receive near-term payments for the coming progress according to the license and collaboration agreement.

Future and Outlook

Looking forward to 2025, we will continue to advance the development of our drug candidates to unleash their therapeutic potential and address substantial unmet medical needs. We will follow a stepwise clinical development strategy to evaluate our drug candidates and expand their clinical application. In addition, we plan to expand our overseas footprint and develop immuno-oncology therapies to fully grasp tremendous market opportunities. We expect to rapidly advance clinical studies in China, and may subsequently utilize the China data to accelerate the clinical progress in other markets in order to save the time and costs of clinical development globally. Also, we will continue to single out and evaluate other innate immune checkpoints and enrich our pipeline with novel therapies.

Cautionary Statement under Rule 18A.08(3) of the Listing Rules: Our Company cannot guarantee that it will be able to successfully develop or ultimately market our Core Product.

FINANCIAL REVIEW

Revenue

	Year ended December 31,	
	2024	2023
	RMB'000	*RMB'000*
Out-licensing fee	**71,342**	—
Collaboration development	**2,668**	—
Revenue from sales of cell strain and other products	**111**	367
Revenue from testing services	**28**	19
Total	**74,149**	386

For the years ended December 31, 2024 and 2023, our Group recorded revenue of RMB74.1 million and RMB0.4 million, respectively. Our revenue was generated from out-licensing fee, collaboration development revenue, sales of cell strain and other products, and provision of testing services. Our revenue generated from out-licensing fee mainly represents the upfront of the license and collaboration agreement we have reached with the Axion Bio, Inc. Our revenue generated from collaboration development represents the clinical development payment we received pursuant to the license and collaboration agreement we have reached with the Axion Bio, Inc. Our revenue generated from sales of cell strain and other products mainly represents the income from selling cell lines and growth medium developed by us. Our revenue generated from testing services mainly represents the income from providing testing assays through fee-for-service contracts.

Other Income

	Year ended December 31,	
	2024	2023
	RMB'000	*RMB'000*
Bank interest income	**6,376**	10,799
Government grants	**5,387**	7,309
Others	**—**	137
Total	**11,763**	18,245

Our other income decreased from RMB18.2 million for the year ended December 31, 2023 to RMB11.8 million during the year ended December 31, 2024, primarily attributable to a decrease in bank interest income of RMB4.4 million.

Other Gains and Losses, Net

	Year ended December 31,	
	2024	2023
	RMB'000	*RMB'000*
Impairment loss for property and equipment	**(27,398)**	—
Gains from changes in fair value of financial assets at FVTPL	**14,151**	1,761
Net foreign exchange gains	**1,790**	96
Others	**(17)**	(79)
Total	**(11,474)**	1,778

Our other gains and losses, net changed from gains of RMB1.8 million for the year ended December 31, 2023 to losses of RMB11.5 million for the year ended December 31, 2024, which was mainly attributable to an increase of RMB27.4 million in impairment loss for property and equipment in accordance with IAS 36 *Impairment of Assets*; partially offset by (i) an increase of RMB12.4 million in gains from changes in fair value of financial assets at FVTPL, mainly due to the gains from the wealth management products, and (ii) an increase of RMB1.7 million in net foreign exchange gains, in connection with fluctuations in the RMB-USD exchange rate.

Research and Development Expenses

	Year ended December 31,	
	2024	2023
	RMB'000	*RMB'000*
Preclinical and CMC expenses	**86,458**	42,883
Clinical trial expenses	**116,608**	120,584
Salaries and related benefit costs	**69,071**	61,629
Costs of materials and consumables	**14,069**	12,304
Share-based payments	**16,816**	31,160
Depreciation expenses	**13,133**	13,950
Others	**6,604**	9,434
Total	**322,759**	291,944

Our research and development expenses consisted of (i) preclinical and CMC expenses, mostly resulting from the engagement of CROs, CDMOs and other service providers to conduct preclinical studies and CMC on our behalf; (ii) clinical trial expenses for our drug candidates, including expenses with respect to the engagement of clinical trial sites and principal investigators, as well as other expenses incurred in connection with our clinical trials; (iii) salaries and related benefit costs (exclusive of non-cash share-based payments) for our research and development activities; (iv) costs of materials and consumables, primarily representing expenses for procuring materials and consumables used to support our preclinical studies and clinical trials; (v) non-cash share-based payments for our research and development functions; (vi) depreciation expenses, mainly including depreciation expenses for right-of-use assets, property and equipment used for research and development purposes; and (vii) others, including utilities, travelling and transportation expenses and other miscellaneous expenses.

Our research and development expenses increased by 10.6% from RMB291.9 million for the year ended December 31, 2023 to RMB322.8 million for the year ended December 31, 2024, primarily due to (i) an increase of RMB43.6 million in preclinical and CMC expenses, primarily due to the increased manufacturing and CDMO expenses of IMM2510 and IMM0306 for the use in their clinical trials; and (ii) an increase of RMB7.4 million in salaries and related benefit costs due to the continuous expansion of our clinical team throughout 2024, in line with our continuous research and development efforts in advancing and expanding our pipeline of drugs; partially offset by a decrease of RMB 18.3 million in clinical trial expenses and Share-based payments due to (i) the decrease of RMB 4.0 million in clinical CRO expenses and laboratories expenses; and (ii) a decrease of RMB14.3 million in share-based payments, resulting from a decrease in the number of restricted shares vested for the year ended December 31, 2024.

Administrative Expenses

Our administrative expenses decreased by 19.4% from RMB80.4 million for the year ended December 31, 2023 to RMB64.8 million for the year ended December 31, 2024, which was mainly caused by the decrease of non-cash share-based payments, resulting from a decrease in the number of restricted shares vested for the year ended December 31, 2024.

Finance Costs

Our finance costs increased from RMB1.5 million for the year ended December 31, 2023 to RMB3.4 million for the year ended December 31, 2024, primarily due to an increase in interest on borrowings.

Income Tax Expense

We recognized no income tax expenses for the years ended December 31, 2023 and 2024.

Loss for the Year

Based on the factors described above, the Group's loss decreased from RMB379.5 million for the year ended December 31, 2023 to RMB316.6 million for the year ended December 31, 2024.

Non-IFRS Measure

To supplement our consolidated statements of profit or loss and other comprehensive expenses which are presented in accordance with IFRSs, we also use adjusted net loss as a non-IFRS measure, which is not required by, or presented in accordance with, IFRSs. We believe that the presentation of the non-IFRS measure when shown in conjunction with the corresponding IFRS measures provides useful information to management and investors in facilitating a comparison of our operating performance from year to year. In particular, the non-IFRS measure eliminates impact of certain expenses/(gains), share-based payment, listing expenses, and impairment loss for property and equipment. Such non-IFRS measure allows investors to consider metrics used by our management in evaluating our performance.

The use of the non-IFRS measure has limitations as an analytical tool, and you should not consider it in isolation from, or as a substitute for, or superior to, analysis of our results of operations or financial condition as reported under IFRSs. In addition, the non-IFRS financial measure may be defined differently from similar terms used by other companies and therefore may not be comparable to similar measures presented by other companies.

The table below sets forth a reconciliation of the loss to adjusted loss during the years indicated:

	Year ended December 31,	
	2024	2023
	RMB'000	*RMB'000*
Loss for the year	**(316,590)**	(379,459)
Added:		
Share-based payment expenses	**34,210**	71,642
Impairment loss for property and equipment	**27,398**	—
Listing expenses	**—**	25,976
Adjusted loss for the year	**(254,982)**	(281,841)

Material Acquisitions and Disposals

On December 30, 2024, the Company entered into an equity transfer agreement (the "**Agreement**") with Shanghai Zhangjiang Group Co., Ltd. (上海張江(集團)有限公司) (the "**Purchaser**") and Shanghai Zhangtou Yaoxin Technology Development Co., Ltd.* (上海張投堯新科技發展有限公司) (the "**Target Company**"), pursuant to which the Company agreed to sell, and the Purchaser agreed to acquire the 100% equity interest of the Target Company (the "**Disposal**"). The maximum amount of the purchase price for the Disposal is RMB98,188,983.55 (the "**Purchase Price**"), subject to the adjustment as stipulated in the Agreement. The Purchase Price was determined after arm's length negotiations between the parties taking into account various factors, including, among others, the valuation of the Target Company conducted as at November 6, 2024 (the "**Valuation Benchmark Date**") by Shanghai Cai Rui Assets Evaluation Co., Ltd* (上海財瑞資產評估有限公司), an independent and qualified valuer engaged by the Purchaser (the "**Valuer**"), using the asset-based approach. According to the valuation report issued on December 24, 2024 (the "**Valuation Report**"), after conducting the evaluation procedures, including on-site investigation, interviews, data collection and evaluation, and internal review, the Valuer concluded that the appraised value of the total assets of the Target Company to be RMB101,078,891.81 as at the Valuation Benchmark Date, based on the asset-based approach.

In February 2025, all the conditions precedent under the Agreement have been fulfilled and the completion of the Disposal took place in accordance with the Agreement. Upon the completion of the Disposal, the Group no longer had any equity interest in the Target Company. As such, the Target Company has ceased to be a subsidiary of the Company and the financial results of the Target Company is no longer be consolidated into the financial statements of the Group. As one or more applicable percentage ratios calculated pursuant to Rule 14.07 of the Listing Rules in respect of the Disposal exceed 5% but are lower than 25%, the Disposal constitutes a discloseable transaction of the Company under relevant requirements of Chapter 14 of the Listing Rules, and is subject to the notification and announcement requirements as set out under Rule 14.34 of the Listing Rules but exempt from the Shareholders' approval requirement under Chapter 14 of the Listing Rules.

As of the Valuation Benchmark Date, the Target Company had no major assets other than the industrial property (the "**Property**") with a land area of approximately 28,763.10 square meters. The Company had initially planned to utilize the Property for construction of its new manufacturing facility. However, taking various factors as below into consideration, the Property is no longer a strategically prioritized asset for the Company, and the Disposal is entered into, among others:

(i) The Company wishes to strategically concentrate on clinical research and development instead of manufacturing. The Group is committed to accelerating advancement of its drug candidates and bring these promising treatments to market as efficiently as possible, therefore the Group is strategically focusing on clinical development; and

(ii) In light of evolving industry dynamics, the Group continues to optimize the use of existing resource, and is refocusing and allocating the Group's resources to expedite clinical development of promising candidates.

To satisfy the Group's strategy and development needs, the Disposal enables the Group to optimize its strategically aligned asset portfolio, and strengthens the cash flow of the Group and allows the Group to improve its liquidity and to reallocate its resources for future development. Accordingly, the Directors (including the independent non-executive Directors) are of the view that the conditions and terms of the Agreement (including the Purchase Price) were fair and reasonable and on normal commercial terms and therefore the Disposal is in the interests of the Company and the Shareholders as a whole. For further details in relation to the Disposal, please refer to the announcements of the Company dated December 30, 2024, February 17, 2025 and February 21, 2025.

Saved as disclosed above, our Group did not have any material acquisitions or disposals of subsidiaries, associates, and joint ventures during the Reporting Period.

Capital Structure, Liquidity and Financial Resources

As of December 31, 2024, our cash and cash equivalents, which were primarily denominated in USD, HKD and RMB and financial assets at fair value through profit or loss were RMB752.1 million aggregately, as compared to RMB608.6 million as of December 31, 2023. The increase was primarily attributed to an increase of RMB73.7 million in our revenue.

As of December 31, 2024, our current assets were RMB867.9 million, including cash and cash equivalents of RMB477.6 million, financial assets at fair value through profit or loss of RMB274.5 million, and prepayments and other receivables of RMB35.6 million. As of December 31, 2024, our current liabilities were RMB214.6 million, including trade and other payables of RMB74.4 million, lease liabilities of RMB6.4 million and bank borrowings of RMB100.9 million.

During the year ended December 31, 2024, net cash used in operating activities of our Group amounted to RMB128.0 million, representing a decrease of RMB239.6 million compared to RMB367.6 million during the year ended December 31, 2023. The decrease was mainly due to the increase of RMB73.7 million and RMB32.9 million in the revenue and contract liabilities, respectively, the decrease of RMB42.5 million in prepayments and other receivables, and the increases of RMB22.9 million in trade and other payables.

During the year ended December 31, 2024, our net cash generated from investing activities increased to RMB37.9 million, compared to the net cash flows used in investing activities of RMB294.8 million for the year ended December 31, 2023. This change was mainly due to the decrease in purchase of financial assets at FVTPL.

During the year ended December 31, 2024, net cash generated from financing activities of our Group decreased by RMB72.1 million to RMB258.9 million from RMB331.0 million during the year ended December 31, 2023, which the decrease was mainly due to the decrease of RMB91.9 million in proceeds from issuance of new shares.

As at December 31, 2024, the Group had available unutilized bank loan facilities of approximately RMB80.1 million.

As part of our treasury management, we invested in certain term deposits, wealth management products and structured deposits to better utilize excess cash when our cash sufficiently covered our ordinary course of business. We have implemented a series of internal control policies and rules setting forth overall principles as well as detailed approval process for our treasury management activities. Going forward, we believe our liquidity requirements will be satisfied by a combination of net proceeds from the Global Offering, funds received from potential collaboration arrangements and cash generated from our operations after the commercialization of our drug candidates.

Gearing Ratio

The gearing ratio (calculated by total liabilities divided by total assets) of the Group as of December 31, 2024 was 26.4%, representing an increase of 12.0% from the gearing ratio of 14.4% as at December 31, 2023, primarily due to an increase in our total liabilities, mainly resulting from (i) an increase of RMB55.4 million in our bank borrowings, and (ii) an increase of RMB32.9 million in contract liabilities which represents the clinical development payment we have received and have yet to deliver the associated collaboration development services.

Indebtedness

As of December 31, 2024, we had unsecured bank borrowings of RMB115.4 million, which were primarily denominated in RMB and with original maturity of within one year, as compared to RMB60.0 million as of December 31, 2023. The interest rate of our bank borrowings ranged from 2.95% to 3.60% as of December 31, 2024.

Our lease liabilities increased from RMB14.8 million as of December 31, 2023 to RMB21.0 million as of December 31, 2024, mainly resulting from the contract renewal of our premises.

Capital Commitments

As of December 31, 2024, we had no capital commitments contracted, but not yet provided. As of December 31, 2023, our Group had capital commitments contracted, but not yet provided, of RMB6.0 million. Such capital commitments reflected capital expenditure we contracted for but not provided in the consolidated financial statements in respect of acquisition of property and equipment.

Contingent Liabilities

As of December 31, 2024, our Group did not have any contingent liabilities.

Pledge of Assets

There was no pledge of our Group's assets as of December 31, 2024.

Foreign Exchange Exposure

Certain financial assets and liabilities of the Group are denominated in foreign currency of respective Group entities which are exposed to foreign currency risk. We currently do not have a foreign currency hedging policy. However, the management monitors foreign exchange exposure and will consider hedging significant foreign currency exposure should the need arise.

Employees and Remuneration Policies

As at December 31, 2024, our Group had 156 employees in total. The total remuneration costs amounted to RMB123.9 million for the year ended December 31, 2024, as compared to RMB155.7 million for the year ended December 31, 2023. The decrease in total remuneration was mainly due to the decrease in non-cash share-based payments, resulting from a decrease in the number of restricted shares vested for the year ended December 31, 2024.

In order to maintain the quality, knowledge and skill levels of our workforce, our Group provides continuing education and training programs, including internal and external training, for our employees to improve their technical, professional or management skills. Our Group also provides training programs to our employees from time to time to ensure their awareness and compliance with our policies and procedures in various aspects.

We provide various incentives and benefits for our employees. We offer competitive salaries, bonuses and share-based compensation to our employees, especially key employees. We have made contributions to social security insurance funds (including pension plans, medical insurance, work-related injury insurance, unemployment insurance and maternity insurance) and housing funds for our employees in accordance with applicable laws. In recognition of the contributions of our employees and to incentivize them to further promote our development, the Company approved and adopted the employee incentive plans on January 31, 2021 and December 20, 2021, respectively. Please refer to the paragraph headed "Appendix IV — Statutory and General Information — C. Further Information about Directors, Supervisors, Management and Substantial Shareholders — 4. Employee Incentive Plans" to the Prospectus for further details.

Significant Investments Held

As at December 31, 2024, we held one cash management fund and one redeemable wealth management product of structured notes (the "**Wealth Management Products**") subscribed from two different reputable institutions using our internal surplus cash reserves, including a Wealth Management Product subscribed from Haitong International Asset Management (HK) Limited ("**Haitong International**") (海通國際資產管理(香港)有限公司) and a Wealth Management Product subscribed from Huatai Financial Holdings (Hong Kong) Limited ("**Huatai Financial**") (華泰金融控股(香港)有限公司), respectively, with effective date of subscription of September 30, 2024 and November 15, 2024, respectively, which recorded a gain on changes in fair value for the Reporting Period of RMB3,480,000 and RMB2,120,000, respectively. As disclosed below, the Company subscribed for a Wealth Management Product of structured notes from Huatai Financial with effective date of subscription of November 10, 2023 and a term for one year. Upon expiry of the term of such wealth management product, the Company agreed to extend it on same terms and conditions with effect from November 15, 2024, and no payment of subscription amount was required or paid by the Company for such extension. The Wealth Management Product subscribed from Haitong International has no expiry date, and the Wealth Management Product subscribed from Haitong International has a term for one year, each of which is redeemable upon giving notice seven business days in advance by the Company. Each of the Wealth Management Products carries an expected annualized rate of return ranging from 1.5% to 4.5%. Such Wealth Management Products had the fair value as of December 31, 2024 of RMB186,019,000 and RMB47,914,000, respectively, each of which accounts for 5% or more of the Group's total assets as of December 31, 2024. For further details of the Wealth Management Product from Haitong International, please refer to the Company's announcement dated September 27, 2024. For further details of the Wealth Management Product from Huatai Financial, see "Discloseable Transactions In Relation To Subscription Of Wealth Management Products" below.

We believe that appropriate wealth management with low risk exposure is conducive to enhancing the utilization of capital and increasing income from idle funds of the Group, and that diversified, readily redeemable investments in cash management products are conducive to enhancing the safety and flexibility of our cash management.

Saved as disclosed above, the Group did not hold any significant investments (including any investment in an investee company) with a value of 5% or more of the Group's total assets as at December 31, 2024.

CORPORATE GOVERNANCE

Compliance with the Corporate Governance Code

The Company is committed to achieving high standards of corporate governance with a view to safeguarding the interests of the Shareholders and to enhancing corporate value and accountability. The Board is of the view that the Company has complied with all applicable code provisions of the Corporate Governance Code during the Reporting Period, except for a deviation from the code provision C.2.1 of the Corporate Governance Code.

Under the code provision C.2.1 of the Corporate Governance Code, the roles of chairman and chief executive should be separate and should not be performed by the same individual. Under the current organization structure of the Company, Dr. Tian Wenzhi (田文志) ("**Dr. Tian**") is the chairman and the chief executive officer of the Company. The Board believes that, in view of his experience, personal profile and his roles in our Company, Dr. Tian is the Director best suited to identify strategic opportunities and focus of the Board due to his extensive understanding of our business as our chief executive officer. The Board also believes that vesting the roles of both chairman and chief executive officer in the same person has the benefit of (i) ensuring consistent leadership within the Group, (ii) enabling more effective and efficient overall strategic planning and execution of strategic initiatives of the Board, and (iii) facilitating the flow of information between the management and the Board for the Group. The Board considers that the balance of power and authority for the present arrangement will not be impaired and this structure will enable our Company to make and implement decisions promptly and effectively. The Board will continue to review and consider splitting the roles of chairman of the Board and the chief executive officer of the Company at a time when it is appropriate by taking into account the circumstances of the Group as a whole.

The Company will continue to review and enhance its corporate governance practices to ensure compliance with the Corporate Governance Code.

Compliance with the Model Code

The Company has adopted a code of conduct regarding the Directors', the Supervisors' and employees' securities transactions on terms no less exacting than the required standards set out in the Model Code.

Having made specific enquiries with all Directors and Supervisors, each of them has confirmed that he/she has complied with our Company's code of conduct regarding the Directors', the Supervisors' and employees' securities transactions during the Reporting Period. No incident of non-compliance of the Model Code by the employees who are likely to be in possession of inside information of the Company was noted by the Company during the Reporting Period.

Completion of the H Share Full Circulation

The Company received the filing notice issued by the CSRC in respect of the conversion of 120,463,260 Unlisted Shares into H Shares (the "**Converted H Shares**") and was granted the listing approval by the Stock Exchange of the listing of and permission to deal in such Converted H Shares on the Main Board of the Stock Exchange on September 3, 2024 (the "**H Share Full Circulation**"). On September 4, 2024, the conversion of 120,463,260 Unlisted Shares into H Shares was completed, and the listing of the Converted H Shares on the Stock Exchange commenced at 9:00 a.m. on September 5, 2024. For further details, please refer to the Company's announcements dated May 29, September 3 and September 4, 2024.

Additionally, on October 25, 2024, the Company has submitted the filing materials with the CSRC in respect of the proposed implementation of H share full circulation, which is to convert an aggregate of 14,114,006 Unlisted Shares into H Shares. As at the date of December 31, 2024, the Company has not completed the filing procedures with the CSRC, and the details of implementation plan of the Conversion and Listing have not been finalized.

Change of Registered Capital

In relation to the Placing (as defined below), the total number of issued Shares of the Company increased from 374,157,695 Shares to 407,307,695 Shares and the total number of issued H Shares increased from 349,013,299 H Shares to 382,163,299 H Shares. As of the date of this announcement, the registered capital of the Company, as recorded with the relevant company registration agency of the PRC was RMB407,307,695, comprising 382,163,299 H Shares of RMB1.00 each and 25,144,396 Unlisted Shares of RMB1.00 each.

USE OF PROCEEDS FROM THE GLOBAL OFFERING

Use of Proceeds during the Reporting Period

The Company issued 17,147,200 H Shares at HK$18.60, which were listed on the Main Board of the Stock Exchange on the Listing Date, and issued 917,800 H Shares at HK$18.60 upon the partial exercise of the Over-allotment Option (as defined in the Prospectus), which were listed on the Main Board of the Stock Exchange on October 4, 2023. We received net proceeds (after deduction of underwriting commissions and related costs and expenses) from the Global Offering (following partial exercise of the Over-allotment Option) (the "**Net Proceeds**") of approximately HK$251.3 million. As at December 31, 2024, the Net Proceeds had been utilized as follows:

Proposed use	**Percentage of total net proceeds**	**Allocation of net proceeds** *(HK$ million)*	**Unutilized amount as of December 31, 2023** *(HK$ million)*	**Utilized amount during the year ended December 31, 2024** *(HK$ million)*	**Balance of net proceeds unutilized as of December 31, 2024** *(HK$ million)*
(a) To fund our Core Product, IMM01	40.0%	100.5	77.7	48.5	29.2
• For funding an ongoing Phase II trial and planned pivotal clinical trials for the combination therapy of IMM01 and azacitidine for the first-line treatment of MDS/AML, and CMML in China, the preparation of relevant registration filings and other regulatory matters.	20.0%	50.3	39.2	17.5	21.7
• For funding ongoing and planned clinical trials of the combination therapy of IMM01 and tislelizumab in China, the preparation of relevant registration filings and other regulatory matters.	17.0%	42.7	31.0	31.0	0.0
• For funding the launch and commercialization of IMM01 in combination therapies.	3.0%	7.5	7.5	0.0	7.5

Proposed use	Percentage of total net proceeds	Allocation of net proceeds *(HK$ million)*	Unutilized amount as of December 31, 2023 *(HK$ million)*	Utilized amount during the year ended December 31, 2024 *(HK$ million)*	Balance of net proceeds unutilized as of December 31, 2024 *(HK$ million)*
(b) To fund our key products, IMM0306, IMM2902 and IMM2520	28.0%	70.4	48.8	43.9	4.9
• For ongoing and planned clinical trials of IMM0306 for the treatment of R/R B-NHL in China, the preparation of relevant registration filings, other regulatory matters, and planned commercial launch in China.	15.0%	37.7	29.5	29.5	0.0
• For the ongoing clinical trials of IMM2902 for the treatment of advanced HER2-positive and HER2-low expressing solid tumors, such as BC, GC, NSCLC and BTC in China and the U.S.	8.0%	20.1	8.1	8.1	0.0
• For planned clinical trials of IMM2520 in China for the treatment of solid tumors, particularly those resistant or not sensitive to the currently available immunotherapies, such as CRC, GC and lung cancer, among others.	5.0%	12.6	11.2	6.3	4.9
(c) For the planned clinical trial of IMM47.	10.0%	25.1	17.5	2.5	15.0
(d) For the ongoing clinical trials of IMM2510 and IMM27M.	5.0%	12.6	5.2	5.2	0.0
(e) For construction of our new manufacturing facility in Zhangjiang Science City, Shanghai.	7.0%	17.5	17.5	0.0	17.5

Proposed use	Percentage of total net proceeds	Allocation of net proceeds *(HK$ million)*	Unutilized amount as of December 31, 2023 *(HK$ million)*	Utilized amount during the year ended December 31, 2024 *(HK$ million)*	Balance of net proceeds unutilized as of December 31, 2024 *(HK$ million)*
(f) For our continuous preclinical research and development of multiple preclinical- and discovery-stage assets, including without limitation IMM4701, IMM51, IMM38, IMM2547, IMM50 and IMM62, as well as CMC to support the clinical trials including pivotal trials for various assets.	5.0%	12.6	12.6	12.6	0.0
(g) For working capital and general corporate purposes.	5.0%	12.6	12.6	12.6	0.0
Total	100.0%	251.3	191.9	125.3	66.6

Proposed Change in Use of Proceeds from the Global Offering

As at the date of this announcement, our Company has not yet utilized the Net Proceeds of approximately RMB54.5 million (the "**Unutilized Net Proceeds**"). The Board, having considered the reasons set out in "Reasons for the Proposed Change in Use of Proceeds from the Global Offering" below, proposed to make adjustments in the intended use of the Unutilized Net Proceeds ("**Proposed Change in Use of Proceeds from the Global Offering**"), as set out in the table below.

	Original percentage of Net Proceeds as disclosed in the Prospectus	Original allocation of Net Proceeds as disclosed in the Prospectus *(HK$ million)*	Amounts of Unutilized Net Proceeds as at the date of this announcement *(HK$ million)*	Amount to be adjusted *(HK$ million)*	Percentage of Net Proceeds (after the proposed change)	Revised allocation of Net Proceeds *(HK$ million)*	Revised amounts of Unutilized Net Proceeds as at the date of this announcement *(HK$ million)*
(a) To fund our Core Product, IMM01	40.0%	100.5	17.1	15.0	46.0%	115.5	32.1
• For funding an ongoing Phase II trial and planned pivotal clinical trials for the combination therapy of IMM01 and azacitidine for the first-line treatment of MDS/AML, and CMML in China, the preparation of relevant registration filings and other regulatory matters.	20.0%	50.3	9.6	Same as original	20.0%	50.3	9.6
• For funding ongoing and planned clinical trials of the combination therapy of IMM01 and tislelizumab in China, the preparation of relevant registration filings and other regulatory matters.	17.0%	42.7	0.0	Same as original	17.0%	42.7	0.0
• For funding the launch and commercialization of IMM01 in combination therapies.	3.0%	7.5	7.5	Same as original	3.0%	7.5	7.5
• For funding ongoing and planned clinical trials of the combination therapy of IMM01	0.0%	0.0	0.0	15.0	6.0%	15.0	15.0

	Original percentage of Net Proceeds as disclosed in the Prospectus	Original allocation of Net Proceeds as disclosed in the Prospectus *(HK$ million)*	Amounts of Unutilized Net Proceeds as at the date of this announcement *(HK$ million)*	Amount to be adjusted *(HK$ million)*	Percentage of Net Proceeds (after the proposed change)	Revised allocation of Net Proceeds *(HK$ million)*	Revised amounts of Unutilized Net Proceeds as at the date of this announcement *(HK$ million)*
(b) To fund our Key Products, IMM0306, IMM2902 and IMM2520	28.0%	70.4	4.9	11.1	32.4%	81.5	16.0
• For ongoing and planned clinical trials of IMM0306 for the treatment of R/R B-NHL in China, the preparation of relevant registration filings, other regulatory matters, and planned commercial launch in China.	15.0%	37.7	0.0	10.0	19.0%	47.7	10.0
• For ongoing and planned clinical trials of IMM0306 for the treatment of SLE, NMOSD, LN and other autoimmune related diseases.	0.0%	0.0	0.0	6.0	2.4%	6.0	6.0
• For the ongoing clinical trials of IMM2902 for the treatment of advanced HER2-positive and HER2-low expressing solid tumors, such as BC, GC, NSCLC and BTC in China and the U.S.	8.0%	20.1	0.0	Same as original	8.0%	20.1	0.0
• For planned clinical trials of IMM2520 in China for the treatment of solid tumors, particularly those resistant or not sensitive to the currently available immunotherapies, such as CRC, GC and lung cancer, among others.	5.0%	12.6	4.9	(4.9)	3.1%	7.7	0.0
(c) For the planned clinical trial of IMM47.	10.0%	25.1	15.0	(15.0)	4.0%	10.1	0.0
(d) For the ongoing clinical trials of IMM2510 and IMM27M.	5.0%	12.6	0.0	Same as original	5.0%	12.6	0.0
(e) For construction of our new manufacturing facility in Zhangjiang Science City, Shanghai.	7.0%	17.5	17.5	(17.5)	0.0%	0.0	0.0

		Original percentage of Net Proceeds as disclosed in the Prospectus	Original allocation of Net Proceeds as disclosed in the Prospectus *(HK$ million)*	Amounts of Unutilized Net Proceeds as at the date of this announcement *(HK$ million)*	Amount to be adjusted *(HK$ million)*	Percentage of Net Proceeds (after the proposed change)	Revised allocation of Net Proceeds *(HK$ million)*	Revised amounts of Unutilized Net Proceeds as at the date of this announcement *(HK$ million)*
(f)	For our continuous preclinical research and development of multiple preclinical-and discovery-stage assets, including without limitation IMM4701, IMM51, IMM38, IMM2547, IMM50 and IMM62, as well as CMC to support the clinical trials including pivotal trials for various assets.	5.0%	12.6	0.0	Same as original	5.0%	12.6	0.0
(g)	For working capital and general corporate purposes.	5.0%	12.6	0.0	6.4	7.6%	19.0	6.4
Total		**100.0%**	**251.3**	**54.5**	**—**	**100.0%**	**251.3**	**54.5**

Reasons for the Proposed Change in Use of Proceeds from the Global Offering

The reasons for the Proposed Change in Use of Proceeds from the Global Offering and the reallocation of the Unutilized Net Proceeds are as follows:

(i) The Company aims to strategically concentrate on the research and development progress of key pipeline projects. The Group is committed to accelerating the advancement of its drug candidates and bringing these promising treatments to market as efficiently as possible, which is why we are focusing on clinical development.

(ii) In light of evolving industry dynamics, the Group continues to optimize the use of existing resources. We are refocusing and reallocating these resources to expedite the clinical development of our most promising candidates. This strategic realignment will enable us to maximize our impact and effectively address the needs of patients.

(iii) As part of this strategy, we have strategically terminated the development of IMM2520, IMM47, and the construction of our manufacturing facility in Zhangjiang Science City, Shanghai, the PRC, and decided to reallocate the Net Proceeds to accelerate the advancement of our drug candidates and efficiently bring these promising treatments to market. For further details of the termination of the construction of our manufacturing facility in Zhangjiang Science City, Shanghai, the PRC, please refer to the announcements of the Company dated December 30, 2024, February 17, 2025 and February 21, 2025.

Impact of the Proposed Change in Use of Proceeds from the Global Offering

The Board has considered that the development direction of our Company is still in line with the disclosures in the Prospectus in spite of the Proposed Change in Use of Proceeds from the Global Offering as stated above. The Board confirms that there is no material change in the business nature of our Group as set out in the Prospectus, and considers that the change in the use of the Net Proceeds is fair and reasonable as this would allow the Group to deploy its financial resources more effectively to enhance the R&D capacity and pipeline of the Group, and is therefore in the best interest of our Company and the Shareholders as a whole.

Save as the changes disclosed above, there are no other proposed changes in the use of the Net Proceeds. The Unutilized Net Proceeds will be applied in a manner consistent with the above planned applications and remains subject to change based on our current and future development of market conditions and actual business needs. The Company plans to utilize the unutilized balance of the Net Proceeds of the Global Offering by the end of 2026. The completion time of using such proceeds will be determined based on the Company's actual business needs and future business development.

General

The Proposed Change in Use of Proceeds from the Global Offering shall be subject to the consideration and approval by the Shareholders at the general meeting of the Company by way of an ordinary resolution. A circular containing, among other things, details of the Proposed Change in Use of Proceeds from the Global Offering, together with a notice of the general meeting of the Company, will be dispatched to the Shareholders in due course.

AUDIT COMMITTEE

The Audit Committee has three members, comprising one non-executive Director, namely Dr. Xu Cong (徐聰), and two independent non-executive Directors, namely Mr. Yeung Chi Tat (楊志達) (chairman), and Dr. Zhenping Zhu.

The Audit Committee has reviewed the accounting principles and practices adopted by the Group and the Group's consolidated financial results for the year ended December 31, 2024, and has discussed and reviewed the risk management, internal control and reporting matters.

SCOPE OF WORK OF MESSRS. DELOITTE TOUCHE TOHMATSU

The figures in respect of the Group's consolidated statement of financial position, consolidated statement of profit or loss and other comprehensive income and the related notes thereto for the year ended December 31, 2024 as set out in this announcement have been agreed by the Group's auditor, Messrs. Deloitte Touche Tohmatsu, to the amounts set out in the audited consolidated financial statements of the Group for the year as approved by the Board on March 25, 2025. The work performed by Messrs. Deloitte Touche Tohmatsu in this respect did not constitute an assurance engagement and consequently no opinion or assurance conclusion has been expressed by Messrs. Deloitte Touche Tohmatsu on the announcement.

IMPORTANT EVENTS AFTER THE REPORTING PERIOD

Amendments to the Articles of Association

To reflect the aforesaid changes in the registered capital of the Company, corresponding amendments were made to the articles of association of the Company (the "**Articles of Association**"). For further details of the amendments to the Articles of Association, please refer to the Company's announcement dated January 24, 2025.

Issuance of Filing Notice by the CSRC for the H Share Full Circulation of Certain Unlisted Shares

The Company has received a filing notice issued by the CSRC (the "**Filing Notice**") regarding the implementation of the H share full circulation of the Company in March 2025. According to the Filing Notice, the Company has completed the filing with the CSRC in respect of the implementation of conversion up to an aggregate of 14,114,006 unlisted shares of the Company into H shares of the Company. The Filing Notice shall be valid for 12 months from March 11, 2025. For further details, please refer to the Company's announcement dated March 14, 2025.

Saved as disclosed in this announcement and as of the date of this announcement, there were no other significant events after the end of the Reporting Period.

PURCHASE, SALE OR REDEMPTION OF LISTED SECURITIES OF THE COMPANY

On November 21, 2024 (before trading hours), the Company and China International Capital Corporation Hong Kong Securities Limited (the "**Placing Agent**") entered into a placing agreement (the "**Placing Agreement**"), pursuant to which the Company has agreed to appoint the Placing Agent, and the Placing Agent has agreed to act as the Company's sole placing agent, to procure subscribers, on a best effort basis, to subscribe for a total of 33,150,000 new H Shares (the "**Placing Shares**") at the placing price of HK$7.05 per Placing Share (the "**Placing Price**") upon the terms and subject to the conditions set out in the Placing Agreement (the "**Placing**").

The Placing was completed on November 28, 2024 in accordance with terms and conditions of the Placing Agreement (the "**Closing**"). A total of 33,150,000 Placing Shares were successfully placed by the Placing Agent to no less than six placees (the "**Placees**") at the Placing Price, representing approximately 8.86% of the number of issued share capital and approximately 9.50% of the total issued H Shares of the Company immediately before Closing, and approximately 8.67% of the total issued H Shares and approximately 8.14% of the number of issued share capital of the Company as enlarged by the allotment and issue of the Placing Shares immediately upon Closing.

To the best of the Directors' knowledge, information and belief, having made all reasonable enquiries, (i) each of the Placees and their respective ultimate beneficial owner(s) (where applicable) is a third party independent of, and not connected with, the Company and its connected persons (as defined in the Listing Rules); and (ii) none of the Placees nor their respective associates (as defined in the Listing Rules) had become a substantial shareholder (as defined in the Listing Rules) of the Company immediately upon Closing.

The net proceeds from the Placing, after deducting the Placing commission and other relevant costs and expenses of the Placing, amounted to approximately HK$229.7 million, representing a net placing price of approximately HK$6.93 per Placing Share.

Details of the use of the proceeds from the Placing are set out below:

Proposed use	Percentage of total net proceeds	Allocation of net proceeds *(HK$ million)*	Utilized amount during the year ended December 31, 2024 *(HK$ million)*	Unutilized amount as of December 31, 2024 *(HK$ million)*
(a) To fund the Phase Ib/II and further clinical studies of IMM2510 in combination with chemotherapy for first-line treatments of NSCLC and triple-negative breast cancer (TNBC) and treatments of other solid tumors in China	30.0%	68.9	1.0	67.9
(b) To fund the Phase Ib and further clinical studies of IMM2510 in combination with IMM27M for the treatment of advanced solid tumors in China	30.0%	68.9	0.8	68.1
(c) To fund the pivotal clinical studies of the combination therapy of IMM01 (Timdarpacept) and azacitidine, and the combination therapy of IMM01 (Timdarpacept) and tislelizumab in China	10.0%	23.0	0.0	23.0
(d) To replenish the Company's working capital and for general corporate purposes	30.0%	68.9	0.0	68.9
Total	100.0%	229.7	1.8	227.9

The Company intends to use the net proceeds from the Placing in the manner consistent with the intended use as mentioned above. The Company plans to utilize the balance of the unutilized net proceeds of the Placing by mid-2027.

For further details in relation to the Placing, please refer to the announcements of the Company dated November 21, 2024 and November 28, 2024.

Save as disclosed above, neither the Company nor any of its subsidiaries has purchased, sold or redeemed any of the Company's listed securities (including sale of treasury Shares (as defined under the Listing Rules)) during the Reporting Period. As at December 31, 2024, the Company did not hold any of treasury share.

FINAL DIVIDEND

The Board has resolved not to recommend a final dividend for the year ended December 31, 2024 (2023: Nil).

DISCLOSEABLE TRANSACTIONS IN RELATION TO SUBSCRIPTION OF WEALTH MANAGEMENT PRODUCTS

Reference is made to the Company's announcement dated March 25, 2024 with respect of the annual results for the year ended December 31, 2023 (the "**2023 Announcement**"). As disclosed in the 2023 Announcement, the Company subscribed for one redeemable wealth management product of structured notes with the principal amount of HK$49,603,273 from Huatai Financial (the "**2023 Subscription**") with effective date of subscription of November 10, 2023 and a term for one year. Upon expiry of the term of the 2023 Subscription, the Company agreed to extend the 2023 Subscription on same terms and conditions with effect from November 15, 2024 (the "**Extension**"), and no payment of subscription amount was required or paid by the Company for the Extension.

In November 2024, the Company agreed to subscribe for a Wealth Management Product in the amount of HK$43,720,000 from Huatai Financial (the "**2024 Subscription**") with effect from December 3, 2024, using its internal surplus cash reserves for the payment of the subscription amount.

The major terms and conditions of the 2024 Subscription are summarised below:

Subscription date:	November 25, 2024
Effective date of the Subscription:	December 3, 2024
Name of the product:	Notes linked to cash management funds
Parties:	(i) Huatai International Financial Products Limited ("**HTIFP**"), as the issuer; (ii) Huatai Financial, as the dealer; and (iii) the Company, as the subscriber
Type of the product:	Structured note
Principal amount subscribed:	HK$43,720,000
Term of investment	One year, redeemable upon giving notice seven business days in advance by the Company
Expected annualised rate of return:	1.5%~4.5%
Investment scope of the product:	Underlying subject of cash management products

Basis of Determination for the Consideration

The Directors confirmed that the consideration for the 2024 Subscription was determined on the basis of commercial terms negotiated at arm's length among the Company and Huatai Financial, having considered the surplus cash reserves of the Group available for treasury management purpose.

Reasons for and Benefits of the 2024 Subscriptions and the Extension

The Directors are of the view that (i) appropriate wealth management with low risk exposure is conducive to enhancing the utilisation of capital and increasing income from idle funds of the Group; (ii) diversified, readily redeemable investments in cash management products are conducive to enhancing the safety and flexibility of cash management; and (iii) the 2024 Subscription was funded by our Group's internal surplus cash reserves and the Extension did not involve additional payment of subscription amount, and therefore would not affect our working capital position or operation. Accordingly, the Directors consider that the terms of the 2024 Subscription and the Extension are fair and reasonable, on normal commercial terms, and in the interests of our Company and our Shareholders as a whole.

Information on Parties

Huatai Financial is a company incorporated in Hong Kong with limited liability on November 23, 2006, and a wholly-owned subsidiary of Huatai Securities Co., Ltd., which is a joint stock company incorporated in the PRC with limited liability and dually listed on the Main Board of the Stock Exchange (stock code: 06886.HK) and the Main Board of Shanghai Stock Exchange (stock code: 601688.SH), respectively. Huatai Financial is licensed with the Securities and Futures Commission of Hong Kong to carry on Type 1 (dealing in securities), Type 4 (advising on securities), and Type 6 (advising on corporate finance) regulated activities as stipulated in the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong). Huatai Financial is principally engaged in securities and futures brokerage.

HTIFP is a company incorporated in British Virgin Islands with limited liability, and an indirect wholly-owned subsidiary of Huatai Securities Co., Ltd. HTIFP is principally engaged in the issuance of structured products and entering into derivative transactions.

As of the date of this announcement and to the best of the Directors' knowledge, information and belief, having made all reasonable enquiries, each of Huatai Financial, HTIFP and their ultimate beneficial owner is a third party independent of each of the Company and its connected persons (as defined under the Listing Rules).

Implications under the Listing Rules

As all the applicable percentage ratios (as defined under Rule 14.07 of the Listing Rules) in respect of each of the 2023 Subscription and 2024 Subscription were below 5%, each of the 2023 Subscription and the 2024 Subscription did not constitute a discloseable transaction of the Company on a standalone basis. The 2023 Subscription and the 2024 Subscription were entered into during a period more than 12 months. With a view to upholding good corporate governance standard, high transparency to Shareholders and investors and for the sake of prudence, and considering that the 2024 Subscription and the Extension were entered into with same counterparty and the 2024 Subscription was made while the 2023 Subscription remained outstanding after the Extension, the Company has aggregated the 2024 Subscription and the Extension for the purpose of determining the Company's obligations under Chapter 14 of the Listing Rules. Since the highest percentage ratio (as calculated under Rule 14.07 of the Listing Rules) of the aforesaid aggregated transactions amounts contemplated under the 2024 Subscription and the Extension was more than 5% but less than 25%, they constituted discloseable transactions of the Company and shall be subject to the reporting and announcement requirements but exempt from the Shareholders' approval requirement under Chapter 14 of the Listing Rules.

Enhanced Measures

The Company believes that the Extension does not constitute a standalone transaction under the Chapter 14 of the Listing Rules as no payment of subscription amount and was involved. Nevertheless, with a view to upholding good corporate governance standard high transparency to Shareholders and investors and for the sake of prudence, the Company has aggregated the 2024 Subscription and the Extension for the purpose of determining the Company's obligations under Chapter 14 of the Listing Rules.

Moving forward, we will continue to enhance internal control procedures in terms of reporting obligations, including, among other things: (i) improving coordination and reporting for notifiable transactions, (ii) regularly reviewing transaction size test calculations, (iii) providing senior management of the Company with regular training on regulatory compliance and (iv) maintaining close collaboration with legal advisors and/or the compliance advisor (if applicable) to ensure ongoing compliance with the Listing Rules. The Company remains committed to complying with the Listing Rules and conducting thorough risk assessment of its wealth management product subscriptions.

PUBLICATION OF ANNUAL RESULTS AND ANNUAL REPORT

This annual results announcement is published on the websites of the Stock Exchange (www.hkexnews.hk) and the Company (www.immuneonco.com).

The annual report for the year ended December 31, 2024 of the Company containing all the information required by the Listing Rules will be despatched to the Shareholders of the Company (if necessary) and published on the websites of the Stock Exchange and the Company in due course.

APPRECIATION

On behalf of the Board, I wish to express my sincere gratitude to our Shareholders and business partners for their continued trust and support, and to our employees for their diligence, dedication, loyalty and integrity.

CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME

FOR THE YEAR ENDED DECEMBER 31, 2024

		Year ended December 31,	
		2024	2023
	Notes	***RMB'000***	*RMB'000*
Revenue	*3*	**74,149**	386
Other income	*5*	**11,763**	18,245
Other gains and losses, net		**(11,474)**	1,778
Research and development expenses		**(322,759)**	(291,944)
Administrative expenses		**(64,820)**	(80,424)
Listing expenses		**—**	(25,976)
Finance costs		**(3,449)**	(1,524)
Loss before tax	*6*	**(316,590)**	(379,459)
Income tax expense	*7*	**—**	—
Loss for the year		**(316,590)**	(379,459)
Other comprehensive expense			
Item that may be reclassified subsequently to profit or loss:			
Exchange differences arising on translation of foreign operations		**(10)**	(172)
Total comprehensive expense for the year		**(316,600)**	(379,631)
Loss for the year attributable to:			
Owners of the Company		**(315,855)**	(379,459)
Non-controlling interests		**(735)**	—
		(316,590)	(379,459)
Total comprehensive expense for the year attributable to:			
Owners of the Company		**(315,865)**	(379,631)
Non-controlling interests		**(735)**	—
		(316,600)	(379,631)
Loss per share			
— Basic and diluted *(RMB yuan)*	*8*	**(0.84)**	(1.05)

CONSOLIDATED STATEMENT OF FINANCIAL POSITION

AT DECEMBER 31, 2024

		As at December 31,	
		2024	2023
	Notes	***RMB'000***	*RMB'000*
Non-current assets			
Property and equipment		**27,646**	59,157
Right-of-use assets		**20,065**	90,230
Other non-current assets		**6,347**	38,503
		54,058	187,890
Current assets			
Trade receivables	*10*	**16**	39
Prepayments and other receivables	*11*	**35,604**	78,097
Financial assets at fair value through profit or loss ("**FVTPL**")		**274,521**	259,085
Term deposits with original maturity over three months		**—**	42,496
Cash and cash equivalents		**477,601**	306,983
		787,742	686,700
Assets classified as held for sale		**80,196**	—
		867,938	686,700
Current liabilities			
Trade and other payables	*11*	**74,431**	51,530
Contract liabilities		**32,900**	—
Borrowings		**100,890**	59,980
Lease liabilities		**6,421**	4,398
		214,642	115,908
Net current assets		**653,296**	570,792
Total assets less current liabilities		**707,354**	758,682

	As at December 31,	
	2024	2023
	RMB'000	*RMB'000*
Non-current liabilities		
Borrowings	**14,500**	—
Lease liabilities	**14,549**	10,395
	29,049	10,395
Net assets	**678,305**	748,287
Capital and reserves		
Share capital	**407,308**	374,158
Reserves	**271,592**	374,129
Equity attributable to owners of the Company	**678,900**	748,287
Non-controlling interests	**(595)**	—
Total equity	**678,305**	748,287

NOTES TO THE FINANCIAL STATEMENTS

1. GENERAL INFORMATION

ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (the "**Company**") was incorporated in the People's Republic of China (the "**PRC**") on June 18, 2015 as a limited liability company. On June 14, 2022, the Company was converted to a joint stock company with limited liability under the Company Law of the PRC. The Company's shares were listed on The Main Board of The Stock Exchange of Hong Kong Limited on September 5, 2023 (the "**Listing**"). The respective address of the registered office and the principal place of business of the Company is Unit 15, 1000 Zhangheng Road, China (Shanghai) Pilot Free Trade Zone, Pudong New Area, Shanghai, PRC.

The principal activities of the Company and its subsidiaries (the "**Group**") are the research and development of immuno-oncology therapies.

The consolidated financial statements are presented in Renminbi ("**RMB**"), which is also the functional currency of the Company.

2. APPLICATION OF NEW AND AMENDMENTS TO INTERNATIONAL FINANCIAL REPORTING STANDARDS ("IFRS") ACCOUNTING STANDARDS

Amendments to IFRS Accounting Standards that are mandatorily effective for the current year

In the current year, the Group has applied the following new and amendments to IFRS Accounting Standards issued by the International Accounting Standards Board (the "**IASB**"), for the first time, which are mandatorily effective for the Group's annual period beginning on January 1, 2024 for the preparation of the Group's consolidated financial statements:

Amendments to IFRS 16	Lease Liability in a Sale and Leaseback
Amendments to IAS 1	Classification of Liabilities as Current or Noncurrent
Amendments to IAS 1	Non-current Liabilities with Covenants
Amendments to IAS 7 and IFRS 7	Supplier Finance Arrangements

The application of these amendments to IFRS Accounting Standards in the current year has had no material impact on the Group's financial positions and performance for the current and prior years and/or on the disclosures set out in these consolidated financial statements.

New and amendments to IFRS Accounting Standards in issue but not yet effective

The Group has not early applied the following amendments to IFRS Accounting Standards that have been issued but are not yet effective:

Amendments to IFRS 10 and IAS 28	Sale or Contribution of Assets between an Investor and its Associate or Joint Venture[1]
Amendments to IFRS 9 and IFRS 7	Amendments to the Classification and Measurement of Financial Instrument[3]
Amendments to IFRS 9 and IFRS 7	Contracts Referencing Nature-dependent Electricity[3]
Amendments to IFRS Accounting Standards	Annual Improvements to IFRS Accounting Standards — Volume 11[3]
Amendments to IAS 21	Lack of Exchangeability[2]
IFRS 18	Presentation and Disclosure in Financial Statements[4]

1 Effective for annual periods beginning on or after a date to be determined.
2 Effective for annual periods beginning on or after January 1, 2025.
3 Effective for annual periods beginning on or after January 1, 2026.
4 Effective for annual periods beginning on or after January 1, 2027.

The application of IFRS 18 has impact on presentation of the consolidated statement of profit or loss and other comprehensive income and no impact on the Group's financial positions and performance. Except for the IFRS 18, the directors of the Company anticipate that the application of these amendments to IFRS Accounting Standards will have no material impact on the Group's consolidated financial statements in the foreseeable future.

3. REVENUE

Disaggregation of revenue from contracts with customers:

	Year ended December 31,	
	2024	2023
	RMB'000	*RMB'000*
Types of goods or services		
Out-licensing fee	**71,342**	—
Collaboration development	**2,668**	—
Sales of cell strain and other products	**111**	367
Testing services	**28**	19
	74,149	386
Geographical market		
United States of America ("**USA**")	**74,010**	—
The PRC	**139**	386
	74,149	386
Timing of revenue recognition		
At a point in time	**71,481**	386
Overtime	**2,668**	—
	74,149	386

Out-licensing

In August 2024, the Company entered into a license and collaboration agreement (the "**License and Collaboration Agreement**") with an independent third party, pursuant to which the Company agreed to grant the customer an exclusive license to research, develop and commercialize certain bispecific antibodies outside the Greater China region, including mainland China, Hong Kong Special Administrative Region of China, Macau Special Administrative Region of China and Taiwan.

Under the License and Collaboration Agreement, the Company will receive upfront payments, clinical development payments, milestone payments and sales-based royalty.

During the year ended December 31, 2024, the Group recognised a total revenue of RMB71,342,000 at a point in time upon the grant of the license, which is the time the customer obtains control on the usage of licensed intellectual property. The normal credit term is 10 to 30 days upon receipt of invoices.

For contract that contains variable consideration in relation to milestone payment and sales-based royalty from license agreement, the Group estimates the amount of consideration to which it will be entitled using the most likely amount, which best predicts the amount of consideration to which the Group will be entitled. The potential milestone payments that the Company is eligible to receive were considered as variable consideration as all milestone amounts were fully constrained due to uncertainty of achievement.

The estimated amount of variable consideration is included in the transaction price only to the extent that it is highly probable that such an inclusion will not result in a significant revenue reversal in the future when the uncertainty associated with the variable consideration is subsequently resolved.

At the end of each reporting period, the Group updates the estimated transaction price (including updating its assessment of whether an estimate of variable consideration is constrained) to represent faithfully the circumstances present at the end of the reporting period and the changes in circumstances during the reporting period.

Collaboration development

Pursuant to the License and Collaboration Agreement, the Group is entitled to receive clinical development payment following the progress of the collaboration development plan. Revenue is recognised over time for the collaboration development services as the customer simultaneously receives and consumes the benefits provided by the Group's performance. The progress towards complete satisfaction of a performance obligation is measured based on output method, which is to recognise revenue on the basis of the Group's performance completed to date.

The normal credit term is 30 days upon receipt of invoices. The transaction price received by the Group is recognised as a contract liability and the Group transfers the contract liabilities to revenue over time on a systematic basis that is consistent with the customer receives and consumes the benefits from the service. As at December 31, 2024, RMB32,900,000 has been received and recorded as contract liability since the service has not yet been performed.

Sales of cell strain and other products

Revenue from sales of cell strain and other products is recognised when control of the goods has been transferred, being when the goods have been delivered to the customer's specific location. Transportation and handling activities that occur before customers obtain control are considered as fulfilment activities. A receivable is recognised by the Group when the goods are delivered to the customer. Following delivery, the customer bears the risks of obsolescence and loss in relation to the goods. The normal credit term is 10 to 30 days (2023: 10 to 30 days) upon delivery.

Testing services

The Group earns revenues by providing testing services to its customers through fee-for-service contracts. Services revenues are recognized at a point of time upon the customer obtains deliverables of the Group's service. The normal credit term is 10 to 30 days (2023: 10 to 30 days) upon delivery of testing result and issuance of invoices.

Revenue is recognised for sales which are considered highly probable that a significant reversal in the cumulative revenue recognised will not occur. All sales of goods or services have an original expected duration of one year or less. As permitted under IFRS 15, the transaction price allocated to these unsatisfied contracts is not disclosed.

4. SEGMENTS INFORMATION

Operating segments are identified on the basis of internal reports about components of the Group that are regularly reviewed by the chief operating decision maker ("**CODM**"), which is also identified as the chief executive officer of the Group, in order to allocate resources to segments and to assess their performance.

During the year, the CODM reviews the overall results and financial position of the Group as a whole which are prepared based on the same material accounting policies. Accordingly, the Group has only one single segment and no further analysis of the single segment is presented.

Geographical information

As at December 31, 2024 and 2023, all non-current assets are located in the PRC.

Information about major customers

Revenue from customers contributing over 10% of the total revenue of the Group during the reporting period are as follows:

	Year ended December 31,	
	2024	2023
	RMB'000	*RMB'000*
Customer A	**74,010**	N/A
Customer B	**N/A**	178
Customer C	**N/A**	80

N/A: Not disclosed as amounts less than 10% of total revenue.

5. OTHER INCOME

	Year ended December 31,	
	2024	2023
	RMB'000	*RMB'000*
Bank interest income	**6,376**	10,799
Government grants *(Note)*	**5,387**	7,309
Others	**—**	137
	11,763	18,245

Note:

The amount represents various subsidies received from the PRC local government authorities as incentives mainly for the Group's research and development activities and financing activities.

6. LOSS BEFORE TAX

	Year ended December 31,	
	2024	2023
	RMB'000	*RMB'000*
Loss before tax for the year has been arrived at after charging:		
Depreciation of property and equipment	**10,277**	12,414
Depreciation of right-of-use assets	**10,404**	10,169
Total depreciation	**20,681**	22,583
Auditor's remuneration	**2,305**	1,560
Directors' and supervisors' emoluments	**27,370**	52,429
Other staff costs:		
— salaries and other benefits	**67,074**	64,301
— discretionary bonus *(Note)*	**7,862**	6,820
— retirement benefit scheme contributions	**6,345**	4,333
— share-based payments	**15,264**	27,854
	123,915	155,737

Note:

Discretionary bonus is determined based on their duties and responsibilities of the relevant individuals within the Group and the Group's performance.

7. INCOME TAX EXPENSE

Under the Law of the PRC on Enterprise Income Tax (the "**EIT Law**") and Implementation Regulation of the EIT Law, the tax rate of the Company and the PRC subsidiaries of the Company is 25% for both years.

Pursuant to Caishui 2018 circular No. 99, the Company enjoyed super deduction of 200% on qualifying research and development expenditures for the year ended December 31, 2024 (Year ended December 31, 2023: 200%).

No provision for taxation in Hong Kong or the United States has been made since the operating subsidiaries of the Company in Hong Kong and the United States have no taxable profits for the year ended December 31, 2024 (Year ended December 31, 2023: nil).

The Group has applied the temporary exception issued by the IASB in May 2023 from the accounting requirements for deferred taxes in IAS 12. Accordingly, the Group neither recognises nor discloses information about deferred tax assets and liabilities related to pillar two income taxes. The pillar two income taxes legislation had no material impact on the Group's financial positions and performance for the current and prior years.

The income tax expense for the reporting period can be reconciled to the loss before tax per the consolidated statements of profit or loss and other comprehensive income as follows:

	Year ended December 31,	
	2024	2023
	RMB'000	*RMB'000*
Loss before tax	**(316,590)**	(379,459)
Tax PRC EIT rate at 25%	**(79,147)**	(94,865)
Tax effect of expenses that are not deductible for tax purpose	**192**	258
Tax effect of super deduction on research and development expenses	**(29,440)**	(45,409)
Tax effect of tax losses not recognized	**85,609**	120,612
Tax effect of deductible temporary differences not recognized	**26,960**	22,910
Utilisation of deductible temporary differences previously not recognized	**(4,174)**	(3,506)
Income tax expense	**—**	—

As at December 31, 2024, the Group has unused tax losses of RMB1,811,969,000 (2023: RMB1,446,377,000) and deductible temporary differences of RMB322,048,000 (2023: RMB231,500,000). No deferred tax asset has been recognized in respect of the tax losses or temporary differences due to the unpredictability of future profit streams.

The unused tax losses will be carried forward and expire in years as follows:

	As at December 31,	
	2024	2023
	RMB'000	*RMB'000*
2024	**—**	1
2025	**398**	398
2026	**11,590**	11,590
2027	**22,163**	22,163
2028	**34,368**	34,368
2029	**78,770**	49,233
2030	**127,109**	127,109
2031	**312,658**	312,658
2032	**405,642**	405,718
2033	**505,759**	482,574
2034	**312,823**	—
2035 and later	**689**	565
	1,811,969	1,446,377

8. LOSS PER SHARE

The calculation of the basic and diluted loss per share is based on the following data:

	Year ended December 31,	
	2024	2023
Loss for the purpose of calculating basic and diluted loss per share:		
Loss for the year attributable to the owners of the Company *(RMB'000)*	**(315,855)**	(379,459)
Number of shares *('000):*		
Weighted average number of ordinary shares for the purpose of basic and diluted loss per share	**377,155**	361,810
Basic and diluted loss per share *(RMB yuan) (Note)*	**(0.84)**	(1.05)

Note:

No adjustment has been made to the basic loss per share presented for the year ended December 31, 2024 and 2023 as the Group had no potentially dilutive ordinary shares in issue during the year.

9. DIVIDENDS

No dividend was paid or declared by the Company for ordinary shareholders of the Company during 2024 (2023: nil), nor has any dividend been proposed since the end of the reporting period.

10. TRADE RECEIVABLES

The following is an aged analysis of trade receivable net of allowance for credit losses presented based on the date of completion of service or delivery of goods at the end of the reporting period:

	As at December 31,	
	2024	2023
	RMB'000	*RMB'000*
Within 30 days	**6**	35
31–60 days	**7**	2
61–120 days	**—**	2
121–180 days	**3**	—
	16	39

The Group normally grants a credit period of 30 days or a particular period agreed with customers effective from the date when the services have been completed or control of goods has been transferred to the customer and billed to the customer.

11. PREPAYMENTS AND OTHER RECEIVABLES

	As at December 31,	
	2024	2023
	RMB'000	*RMB'000*
Other receivables:		
Deposits for plant construction	**9,851**	—
Interest receivables	**—**	909
Others	**168**	131
Prepayments for:		
Purchasing goods and research and development services	**24,543**	76,769
Others	**1,042**	288
	35,604	78,097

12. TRADE AND OTHER PAYABLES

	As at December 31,	
	2024	2023
	RMB'000	*RMB'000*
Trade payables for research and development expenses	**43,244**	10,804
Accrued outsourcing research and development expenses	**10,985**	14,191
Accrued staff costs and benefits	**15,903**	14,163
Accrued research and development materials and consumables	**1,149**	942
Accrued issue costs	**287**	299
Accrued listing expenses	**—**	3,440
Payables for property and equipment	**515**	5,185
Legal and professional fees	**549**	1,560
Other tax payables	**1,114**	765
Others	**685**	181
	74,431	51,530

The average credit period on purchases of goods/services of the Group is 45 days.

The following is an aged analysis of trade payables presented based on the invoice dates at the end of the reporting period:

	As at December 31,	
	2024	2023
	RMB'000	*RMB'000*
0–30 days	**42,792**	10,746
31–90 days	**—**	42
91–180 days	**452**	16
	43,244	10,804

In this announcement, the following expressions shall have the meanings set out below unless the context requires otherwise:

"Audit Committee"	the audit committee of the Board
"Board"	the board of Directors of our Company
"China" or "PRC"	the People's Republic of China and, for the purpose of this announcement, excludes Hong Kong, the Macao Special Administrative Region of the PRC and Taiwan, China
"Company" or "our Company"	ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (宜明昂科生物醫藥技術(上海)股份有限公司), a joint stock company incorporated in the PRC with limited liability on June 14, 2022, the H Shares of which are listed on the Stock Exchange (stock code: 1541), or, where the context requires (as the case may be), its predecessor, ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. (宜明昂科生物醫藥技術(上海)有限公司), a limited liability company established in the PRC on June 18, 2015
"Core Product"	IMM01 (Timdarpacept), the designated "core product" as defined under Chapter 18A of the Listing Rules
"Corporate Governance Code"	the Corporate Governance Code set out in Appendix C1 to the Listing Rules
"connected person(s)"	has the meaning ascribed to it under the Listing Rules
"CSRC"	the China Securities Regulatory Commission (中國證券監督管理委員會)
"Director(s)"	the director(s) of the Company
"Dr. Tian"	Dr. Tian Wenzhi (田文志), the chairman of the Board, the chief executive officer, the chief scientific officer and the executive Director of our Company, and one of our Controlling Shareholders

"General Mandate"	The general and unconditional mandate granted to the Board to allot, issue and/or deal with up to 74,831,539 new Shares, representing 20% of the total issued Shares as at the date of the special resolution of the Shareholders passed at the annual general meeting of the Company held on May 28, 2024
"Global Offering"	the global offering of the Company's H Shares on the Stock Exchange
"Group", "our Group", "we", "us" or "our"	our Company and all of its subsidiaries, or any one of them as the context may require or, where the context refers to any time prior to its incorporation, the business which its predecessors or the predecessors of its present subsidiaries, or any one of them as the context may require, were or was engaged in and which were subsequently assumed by it
"H Share(s)"	overseas listed foreign share(s) in the share capital of our Company with a nominal value of RMB1.00 each, which is/are subscribed for and traded in Hong Kong dollars and listed on the Stock Exchange
"HKD" or "HK$"	Hong Kong dollars, the lawful currency of Hong Kong
"Hong Kong"	the Hong Kong Special Administrative Region of the People's Republic of China
"IFRS"	International Financial Reporting Standards, which include standards, amendments and interpretations promulgated by the International Accounting Standards Board and the International Accounting Standards and interpretations issued by the International Accounting Standards Committee
"Listing Date"	September 5, 2023, being the date on which the H Shares were listed and from which dealings therein were permitted to take place on the Stock Exchange
"Listing Rules"	the Rules Governing the Listing of Securities on the Stock Exchange, as amended from time to time
"Model Code"	the Model Code for Securities Transactions by Directors of Listed Issuers set out in Appendix C3 to the Listing Rules

"NMPA"	the National Medical Products Administration of the PRC (國家藥品監督管理局), successor to the China Food and Drug Administration or CFDA (國家食品藥品監督管理總局)
"Prospectus"	the prospectus of the Company dated August 24, 2023
"R&D"	research and development
"Reporting Period"	the financial year ended December 31, 2024
"RMB"	Renminbi, the lawful currency of the PRC
"Share(s)"	ordinary share(s) in the share capital of our Company with a nominal value of RMB1.00 each, comprising the Unlisted Shares and H Shares
"Shareholder(s)"	holder(s) of the Share(s)
"Stock Exchange"	The Stock Exchange of Hong Kong Limited
"subsidiary(ies)"	has the meaning ascribed to this term under the Listing Rules
"substantial shareholder(s)"	has the meaning ascribed to it under the Listing Rules
"Supervisor(s)"	the supervisor(s) of the Company
"U.S." or "United States"	the United States of America, its territories, its possessions and all areas subject to its jurisdiction
"Unlisted Share(s)"	ordinary share(s) issued by our Company with a nominal value of RMB1.00 each, which is/are not listed on any stock exchange

"USD" or "US$"	United States dollars, the lawful currency of the United States
"%"	per cent.

By order of the Board
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
宜明昂科生物醫藥技術（上海）股份有限公司
Tian Wenzhi
Chairman and Executive Director

Shanghai, the People's Republic of China, March 25, 2025

As at the date of this announcement, the Board of Directors comprises (i) Dr. Tian Wenzhi, Mr. Li Song and Ms. Guan Mei as executive Directors; (ii) Dr. Xu Cong as non-executive Director; and (iii) Dr. Zhenping Zhu, Dr. Kendall Arthur Smith and Mr. Yeung Chi Tat as independent non-executive Directors.